EW - Strategic Sale: Catherine Szyman Decides To Exercise Options Worth $2.32M At Edwards Lifesciences | Benzinga
A significant insider transaction involving the exercise of company stock options was reported on February 15, by Catherine Szyman, CVP at Edwards Lifesciences (NYSE:EW), as per the latest SEC filing.
What Happened: Szyman, CVP at Edwards Lifesciences, exercised stock options for 47,000 shares of EW stock. This information was disclosed in a Form 4 filing with the U.S. Securities and Exchange Commission on Thursday. The exercise price of the options was $36.75 per share.
The Friday morning update indicates Edwards Lifesciences shares down by 0.0%, currently priced at $86.04. At this value, Szyman's 47,000 shares are worth $2,316,630.
Discovering Edwards Lifesciences: A Closer Look
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter valve technologies, surgical clips, catheters, and monitoring systems used to measure a patient's heart function during surgery. The firm derives about 55% of its total sales from outside the U.S.
Financial Insights: Edwards Lifesciences
Revenue Growth: Edwards Lifesciences's remarkable performance in 3 months is evident. As of 31 December, 2023, the company achieved an impressive revenue ...